Search clinical trials for: ANPD001

Total 17 results

Aspen Neuroscience
California Institute for Regenerative Medicine (CIRM)

Enrolling by invitation

Phase 1/2a Study of ANPD001 in Parkinson Disease (ASPIRO)

Parkinson Disease

United States
Basilea Pharmaceutica

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Fungal Infection

Netherlands
Basilea Pharmaceutica

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Basilea Pharmaceutica

Completed

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Fungal Infection

United Kingdom
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
Pfizer

Completed

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris (APEX)

Candidemia | Candida Infection | Invasive Candidiases

South Africa
Pfizer

Terminated

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds (AEGIS)

Invasive Fungal Infections

Israel, Germany, United States, Belgium
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Pfizer

Completed

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

Candidemia

Germany, United States, Israel, Spain, Belgium
Basilea Pharmaceutica

Completed

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Invasive Fungal Infections

United States
NeuroBo Pharmaceuticals Inc.

Completed

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Healthy

United States
Origin Inc.

Completed

APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults (APT-14-002)

Foot Ulcer, Diabetic

United States
NeuroBo Pharmaceuticals Inc.

Completed

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

COVID-19

United States
Basilea Pharmaceutica
The Clinical Trials Centre Cologne

Completed

Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia

Acute Myeloid Leukemia

Germany
Basilea Pharmaceutica

Completed

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Fungal Infection

Netherlands

3

Subscribe